Rüdiger Ritter
Medical Science Liaison (Msl) Oncology & Rare Diseases @Deciphera Pharmaceuticals
Signup · Get unlimited contacts
WORK HISTORY
Medical Science Liaison (Msl) Oncology & Rare Diseases @Deciphera Pharmaceuticals
Driving scientific exchange and medical strategy for innovative kinase inhibitors in Rare Disease Oncology:As one of three MSLs in Germany, I am responsible for the scientific communication and KOL engagement within the North-West territory.Medical Indications- advanced Gastrointestinal Stromal Tumors (GIST)- Tenosynovial Giant Cell Tumors (TGCT)Key Responsibilities & Focus- KOL Engagement: Building and maintaining strategic relationships with oncologists and surgeons in specialized centers- Scientific Exchange: Translating complex clinical data into actionable insights to support evidence-based treatment decisions- Medical Strategy: Collaborating cross-functionally to support product launches, clinical initiatives and medical projects- Community Support: Serving as a primary scientific point of contact for HCPs to improve the patient journey.
EDUCATION
Johannes Gutenberg University Mainz
Diplom-Biologe (German degree)
ABOUT RÜDIGER RITTER
Bringing 8+ years of Medical Affairs experience to Oncology and Rare Diseases:As a MSL at Deciphera Pharmaceuticals, I am dedicated to supporting healthcare professionals with high-quality scientific exchange in the field of Oncology. My goal is to be a reliable partner, helping you navigate complex data to optimize patient outcomes.Rare Disease Expertise:My background includes successfully managing Rare Disease indications (e.g, at Alexion), where I developed a deep understanding of the unique challenges faced by specialists and patients.Scientific Agility:With a proven ability to master new therapeutic areas quickly and a strong foundation in Immunology, I am your reliable partner for navigating current studies and literature.Strategic Collaboration:From advisory boards to large-scale symposia, I have a track record of connecting Key Opinion Leaders (KOLs) and facilitating meaningful scientific dialogue.Transitioning from Neurology and Vaccines to Oncology, I bring a fresh, interdisciplinary perspective combined with a certified understanding of Market Access. I look forward to exchanging ideas on the latest therapeutic advancements.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.